rheumatology | pharmaphorum

Skip to main content

Thursday 14 November 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

rheumatology

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

News

EULAR 2024

J&J’s nipocalimab raises hope for Sjogren’s patients

Johnson & Johnson’s ‘Swiss army knife’ for autoimmune diseases – FcRn inhibitor nipocalimab – has shown efficacy in Sjogren’s disease (SjD), an autoimmune condition that affects million

News

Novartis' Cosentyx (secukinumab)

Amid tough competition, Novartis makes case for rheumatology...

Swiss pharma hopes to bounce back from Q1 sales disappointment

UK & Europe

otezla_p_cmyk

NICE says Otezla's bargain price offsets lower efficacy

Otezla cheap and convenient, but less effective than rivals, says NICE.

News

Acute pain in a woman hand. Isolation on a white background

Russian rival to GSK/Janssen's RA drug revealed

R-Pharm has a mid-stage rival.

News

one of many. Many of the same bottle, with a focus on one of them.

Janssen's RA candidate among hot topics at EULAR

But attendees warned to expect "oceanic" weather.

Load more results

Editor's Picks

Alligator pancreatic cancer drug 'nearly doubles' survival

Trump claims comprehensive victory in US election

Novo sheds kidney drug licensed for $1.3bn a year ago

AZ confirms China president has been detained

UK health data ecosystem 'is hampering research'

News

Amgen plays down safety concern with obesity candidate

Amgen plays down safety concern with obesity candidate

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

pushing two jigsaw pieces together

Sponsored

Enabling site success: Key insights to reducing burden and i...

Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company